Literature DB >> 33284091

Myostatin deficiency not only prevents muscle wasting but also improves survival in septic mice.

Masayuki Kobayashi1, Shingo Kasamatsu1, Shohei Shinozaki1, Shingo Yasuhara1, Masao Kaneki1.   

Abstract

Sepsis remains a leading cause of mortality in critically ill patients. Muscle wasting is a major complication of sepsis and negatively affects clinical outcomes. Despite intense investigation for many years, the molecular mechanisms underlying sepsis-related muscle wasting are not fully understood. In addition, a potential role of muscle wasting in disease development of sepsis has not been studied. Myostatin is a myokine that downregulates skeletal muscle mass. We studied the effects of myostatin deficiency on muscle wasting and other clinically relevant outcomes, including mortality and bacterial clearance, in mice. Myostatin deficiency prevented muscle atrophy along with inhibition of increases in muscle-specific RING finger protein 1 (MuRF-1) and atrogin-1 expression and phosphorylation of signal transducer and activator of transcription protein 3 (STAT3; major players of muscle wasting) in septic mice. Moreover, myostatin deficiency improved survival and bacterial clearance of septic mice. Sepsis-induced liver dysfunction, acute kidney injury, and neutrophil infiltration into the liver and kidney were consistently mitigated by myostatin deficiency, as indicated by plasma concentrations of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and neutrophil gelatinase-associated lipocalin (NGAL) and myeloperoxidase activity in the organs. Myostatin deficiency also inhibited sepsis-induced increases in plasma high-mobility group protein B1 (HMGB1) and macrophage inhibitory cytokine (MIC)-1/growth differentiation factor (GDF)-15 concentrations. These results indicate that myostatin plays an important role not only in muscle wasting but also in other clinically relevant outcomes in septic mice. Furthermore, our data raise the possibility that muscle wasting may not be simply a complication, but myostatin-mediated muscle cachexia and related changes in muscle may actually drive the development of sepsis as well.NEW & NOTEWORTHY Muscle wasting is a major complication of sepsis, but its role in the disease development is not known. Myostatin deficiency improved bacterial clearance and survival and mitigated damage in the liver and kidney in septic mice, which paralleled prevention of muscle wasting. These results raise the possibility that muscle wasting may not simply be a complication of sepsis, but myostatin-mediated cachexic changes may have a role in impaired bacterial clearance and mortality in septic mice.

Entities:  

Keywords:  bacterial clearance; mortality; muscle wasting; myostatin; sepsis

Mesh:

Substances:

Year:  2020        PMID: 33284091      PMCID: PMC8194407          DOI: 10.1152/ajpendo.00161.2020

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  66 in total

1.  Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member.

Authors:  A C McPherron; A M Lawler; S J Lee
Journal:  Nature       Date:  1997-05-01       Impact factor: 49.962

2.  A deletion in the myostatin gene causes the compact (Cmpt) hypermuscular mutation in mice.

Authors:  G Szabó; G Dallmann; G Müller; L Patthy; M Soller; L Varga
Journal:  Mamm Genome       Date:  1998-08       Impact factor: 2.957

3.  Protein metabolism and gene expression in skeletal muscle of critically ill patients with sepsis.

Authors:  Maria Klaude; Maiko Mori; Inga Tjäder; Thomas Gustafsson; Jan Wernerman; Olav Rooyackers
Journal:  Clin Sci (Lond)       Date:  2012-02       Impact factor: 6.124

4.  Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy.

Authors:  M D Gomes; S H Lecker; R T Jagoe; A Navon; A L Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

5.  Myostatin gene inactivation prevents skeletal muscle wasting in cancer.

Authors:  Yann S Gallot; Anne-Cécile Durieux; Josiane Castells; Marine M Desgeorges; Barbara Vernus; Léa Plantureux; Didier Rémond; Vanessa E Jahnke; Etienne Lefai; Dominique Dardevet; Georges Nemoz; Laurent Schaeffer; Anne Bonnieu; Damien G Freyssenet
Journal:  Cancer Res       Date:  2014-10-21       Impact factor: 12.701

6.  A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle.

Authors:  L Grobet; L J Martin; D Poncelet; D Pirottin; B Brouwers; J Riquet; A Schoeberlein; S Dunner; F Ménissier; J Massabanda; R Fries; R Hanset; M Georges
Journal:  Nat Genet       Date:  1997-09       Impact factor: 38.330

7.  Hormone, cytokine, and nutritional regulation of sepsis-induced increases in atrogin-1 and MuRF1 in skeletal muscle.

Authors:  Robert A Frost; Gerald J Nystrom; Leonard S Jefferson; Charles H Lang
Journal:  Am J Physiol Endocrinol Metab       Date:  2006-09-26       Impact factor: 4.310

8.  Low skeletal muscle area is a risk factor for mortality in mechanically ventilated critically ill patients.

Authors:  Peter J M Weijs; Wilhelmus G P M Looijaard; Ingeborg M Dekker; Sandra N Stapel; Armand R Girbes; H M Oudemans-van Straaten; Albertus Beishuizen
Journal:  Crit Care       Date:  2014-01-13       Impact factor: 9.097

9.  Growth differentiation factor-15 is associated with muscle mass in chronic obstructive pulmonary disease and promotes muscle wasting in vivo.

Authors:  Mehul S Patel; Jen Lee; Manuel Baz; Claire E Wells; Susannah Bloch; Amy Lewis; Anna V Donaldson; Benjamin E Garfield; Nicholas S Hopkinson; Amanda Natanek; William D-C Man; Dominic J Wells; Emma H Baker; Michael I Polkey; Paul R Kemp
Journal:  J Cachexia Sarcopenia Muscle       Date:  2015-12-29       Impact factor: 12.910

10.  Progressive loss of muscle mass could be an adverse prognostic factor of 28-day mortality in septic shock patients.

Authors:  Dong-Woo Seo; Kyung Won Kim; Chang Hwan Sohn; Seung Mok Ryoo; Youn-Jung Kim; Ahn Shin; Won Young Kim
Journal:  Sci Rep       Date:  2019-11-11       Impact factor: 4.379

View more
  7 in total

1.  Enrichment of Newly Synthesized Proteins following treatment of C2C12 Myotubes with Endotoxin and Interferon-γ.

Authors:  Catherine S Coleman; Bruce A Stanley; Charles H Lang
Journal:  Inflammation       Date:  2022-01-14       Impact factor: 4.657

Review 2.  Myostatin/Activin Receptor Ligands in Muscle and the Development Status of Attenuating Drugs.

Authors:  Buel D Rodgers; Christopher W Ward
Journal:  Endocr Rev       Date:  2022-03-09       Impact factor: 25.261

Review 3.  Delivery of Oligonucleotides: Efficiency with Lipid Conjugation and Clinical Outcome.

Authors:  Phuc Tran; Tsigereda Weldemichael; Zhichao Liu; Hong-Yu Li
Journal:  Pharmaceutics       Date:  2022-02-01       Impact factor: 6.321

4.  Molecular and Metabolic Mechanism of Low-Intensity Pulsed Ultrasound Improving Muscle Atrophy in Hindlimb Unloading Rats.

Authors:  Lijun Sun; Shasha An; Zhihao Zhang; Yaling Zhou; Yanan Yu; Zhanke Ma; Xiushan Fan; Liang Tang; Jianzhong Guo
Journal:  Int J Mol Sci       Date:  2021-11-09       Impact factor: 5.923

5.  Identification and Evaluation of Traditional Chinese Medicine Natural Compounds as Potential Myostatin Inhibitors: An In Silico Approach.

Authors:  Shahid Ali; Khurshid Ahmad; Sibhghatulla Shaikh; Jeong Ho Lim; Hee Jin Chun; Syed Sayeed Ahmad; Eun Ju Lee; Inho Choi
Journal:  Molecules       Date:  2022-07-04       Impact factor: 4.927

6.  Myostatin Knockout Regulates Bile Acid Metabolism by Promoting Bile Acid Synthesis in Cattle.

Authors:  Di Wu; Mingjuan Gu; Zhuying Wei; Chunling Bai; Guanghua Su; Xuefei Liu; Yuefang Zhao; Lei Yang; Guangpeng Li
Journal:  Animals (Basel)       Date:  2022-01-15       Impact factor: 2.752

7.  Protective effects of farnesyltransferase inhibitor on sepsis-induced morphological aberrations of mitochondria in muscle and increased circulating mitochondrial DNA levels in mice.

Authors:  Daisuke Tsuji; Harumasa Nakazawa; Tomoko Yorozu; Masao Kaneki
Journal:  Biochem Biophys Res Commun       Date:  2021-04-09       Impact factor: 3.575

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.